Integration of CRISPR-Cas9 Screens and Multi-Omics Profiling Reveals CHD7-ANGPT1 as a Novel Multi-Drug Resistance Axis in AML [ATAC-seq]
To explore how the loss of function of CHD7 leads to drug resistance in acute myeloid leukemia (AML) cells, we investigated the transcriptional programs regulated by CHD7 in OCI-AML2 cells under different drug treatment conditions. This study aims to uncover the role of CHD7 in drug sensitivity and resistance, providing a theoretical basis for developing new therapeutic strategies. Overall design: Assessment of gene expression changes in CHD7 knockdown and control sgSC cells under three different conditions:DMSO,Gilteritinib,Venetoclax.